Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04404088 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment reopened Enrollment increased: 60 → 80 participants · Eligibility criteria expanded, about 8 words · Secondary endpoints: details revised at 7 of 7 entries · 2 more Show 5 more changesShow less
    • Enrollment increased: 60 → 80 participants
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Study description revised
    • Site details revised
  2. 3 versions Re-verified since Apr 13, 2026, no change to tracked fieldsv14-v16
  3. Primary and study completion dates: Mar 1, 2025 to Mar 1, 2028v13
  4. Re-verified, no change to tracked fieldsv12
  5. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 24 to confirmed 60 · Site details revisedv11 Show 2 more changesShow less
    • Enrollment target: estimated 24 to confirmed 60
    • Site details revised
Show 9 earlier versionsHide 9 earlier versions
  1. 6 versions Re-verified since Aug 21, 2020, no change to tracked fieldsv5-v10
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Aug 1, 2020 to Jul 16, 2020 · Site details revisedv4 Show 2 more changesShow less
    • Start date: Aug 1, 2020 to Jul 16, 2020
    • Site details revised
  3. Start date: May 27, 2020 to Aug 1, 2020v3
  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a follicular lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib, lenalidomide, and rituximab may help to control the disease.
Trial Details
NCT Number NCT04404088
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov